Technology | Mammography | December 07, 2018

FDA Clears iCAD's ProFound AI for Digital Breast Tomosynthesis

Artificial intelligence-based technology improves cancer detection rates 8 percent on average, decreases unnecessary patient recalls 7 percent

FDA Clears iCAD's ProFound AI for Digital Breast Tomosynthesis

December 7, 2018 — iCAD Inc. announced clearance by the U.S. Food and Drug Administration (FDA) for their latest, deep-learning, cancer detection software solution for digital breast tomosynthesis (DBT), ProFound AI. The solution built on artificial intelligence (AI) is now available to healthcare facilities in the U.S.

The FDA clearance is based on positive clinical results from a large reader study completed earlier this year and presented at the 2018 Radiological Society of North America (RSNA) annual meeting, Nov. 25-30 in Chicago. The research was performed with 24 radiologists who read 260 tomosynthesis cases both with and without iCAD’s ProFound AI solution. The findings show increased cancer detection rates, reduced false positive rates and patient recalls, and a significant decrease in interpretation times.

“This technology shows tremendous promise in assisting radiologists in detecting cancers, reducing recalls and increasing efficiency when reading tomosynthesis studies,” said Emily Conant, M.D., professor and chief, Division of Breast Imaging, vice chair of faculty development, Department of Radiology at the Hospital of the University of Pennsylvania. “Clinical data shows that when tomosynthesis readers use the ProFound AI algorithm, case-level sensitivity is improved by 8 percent on average and reading times are significantly decreased. Radiologists with various levels of expertise may benefit from this AI-driven technology when reading large tomosynthesis data sets.”

ProFound AI is a high-performance, deep-learning, cancer detection and workflow solution for DBT, delivering improvement of cancer detection rates by an average of 8 percent and decreasing unnecessary patient recall rates by an average of 7 percent. The new technology is trained to detect malignant soft-tissue densities and calcifications. It also provides radiologists with scoring information representing the likelihood that a detection or case is malignant based on the large dataset of clinical images used to train the algorithm.

In addition to improving clinical performance related to breast cancer detection and false positive rates, study results showed ProFound AI can reduce radiologists’ reading time by more than 50 percent on average. An increase in reading time has been a significant challenge for radiologists when moving from 2-D to 3-D mammography.

The solution is currently available for use with - DBT systems in the U.S., Canada and Europe.

For more information: www.icadmed.com

Related Content

HHS Extends Comment Period for Proposed Electronic Health Information Interoperability Rules
News | Electronic Medical Records (EMR) | April 19, 2019
The U.S. Department of Health and Human Services (HHS) is extending the public comment period by 30 days for two...
FDA Clears GE's Deep Learning Image Reconstruction Engine
Technology | Computed Tomography (CT) | April 19, 2019
GE Healthcare has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) of its Deep Learning Image...
In a demonstration on the exhibit floor of the SBI symposium, Koios software identified suspicious lesions in ultrasound images

In a demonstration on the exhibit floor of the SBI symposium, Koios software identified suspicious lesions in ultrasound images. Photo by Greg Freiherr

Feature | Artificial Intelligence | April 19, 2019 | By Greg Freiherr
Commercial efforts to develop...
Artificial Intelligence Performs As Well As Experienced Radiologists in Detecting Prostate Cancer
News | Artificial Intelligence | April 18, 2019
University of California Los Angeles (UCLA) researchers have developed a new artificial intelligence (AI) system to...
Videos | Breast Imaging | April 18, 2019
In a keynote lecture at the Society of Breast Imaging (SBI)/American College of Radiology (ACR) 2019 Symposium, ...
Atrium Health Debuts Amazon Alexa Skill to Help Patients Access Medical Care
News | Artificial Intelligence | April 18, 2019
Atrium Health patients will now be able to use Amazon’s electronic voice system Alexa to not only locate the nearest...
Fatty tissue and breast density may be considered in the context of many factors that affect the occurrence and detection of breast cancer

Fatty tissue and breast density may be considered in the context of many factors that affect the occurrence and detection of breast cancer. Permission to publish provided by DenseBreast-info.org

Feature | Breast Imaging | April 18, 2019 | By Greg Freiherr
When planning a screening program to detect the early signs of breast cancer, age is a major consideration.
Oxipit Introduces Multilingual Support for ChestEye AI Imaging Suite
News | Artificial Intelligence | April 16, 2019
The CE-certified ChestEye artificial intelligence (AI) imaging suite by Oxipit is now available in seven European...